Locke, F. L., Rossi, J. M., Neelapu, S. S., Jacobson, C. A., Miklos, D. B., Ghobadi, A., . . . Bot, A. (2020). Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. Blood advances, 4(19), 4898-4911. https://doi.org/10.1182/bloodadvances.2020002394
Chicago-Zitierstil (17. Ausg.)Locke, Frederick L., et al. "Tumor Burden, Inflammation, and Product Attributes Determine Outcomes of Axicabtagene Ciloleucel in Large B-cell Lymphoma." Blood Advances 4, no. 19 (2020): 4898-4911. https://doi.org/10.1182/bloodadvances.2020002394.
MLA-Zitierstil (9. Ausg.)Locke, Frederick L., et al. "Tumor Burden, Inflammation, and Product Attributes Determine Outcomes of Axicabtagene Ciloleucel in Large B-cell Lymphoma." Blood Advances, vol. 4, no. 19, 2020, pp. 4898-4911, https://doi.org/10.1182/bloodadvances.2020002394.